Gold prices dip as hawkish Fed minutes weigh ahead of Jackson Hole
Acadia Pharmaceuticals (NASDAQ:ACAD), a $4.2 billion market cap company that has delivered an impressive 58% return over the past year, reported that Executive Vice President and Chief Financial Officer Mark C. Schneyer sold 22,000 shares of common stock on August 18, 2025, for a total of $554,023. The sales were executed at a weighted average price of $25.1829, with individual sales prices ranging from $25.06 to $25.28.
Following the transaction, Schneyer directly owns 40,130 shares of Acadia Pharmaceuticals. The sale was conducted under a Rule 10b5-1 trading plan adopted on May 19, 2025.
In other recent news, Acadia Pharmaceuticals reported its second-quarter 2025 earnings, surpassing Wall Street expectations with an earnings per share of $0.16 compared to the forecast of $0.14. The company achieved revenue of $264.6 million, slightly ahead of the projected $262.44 million. Acadia’s Nuplazid sales were reported at $168.5 million, aligning with consensus expectations, while Daybue sales reached $96.1 million, exceeding estimates. Following these results, Citizens JMP raised its price target on Acadia Pharmaceuticals to $38 from $37, maintaining a Market Outperform rating. Stifel also adjusted its price target upward to $24 from $18, citing solid execution for Nuplazid and Daybue. Mizuho (NYSE:MFG), on the other hand, had mixed reactions, initially reducing its price target to $22 from $32 due to certain shortfalls but later raising it to $24 from $23 after evaluating solid earnings. These developments reflect a varied response from analysts, with differing perspectives on Acadia’s financial outlook.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.